866-997-4948(US-Canada Toll Free)

Ischemia Reperfusion Injury - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 154 Pages

Ischemia Reperfusion Injury - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2017, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 4, 1, 29 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 4 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 4
Ischemia Reperfusion Injury - Overview 5
Ischemia Reperfusion Injury - Therapeutics Development 6
Ischemia Reperfusion Injury - Therapeutics Assessment 20
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 30
Ischemia Reperfusion Injury - Drug Profiles 40
Ischemia Reperfusion Injury - Dormant Projects 142
Ischemia Reperfusion Injury - Discontinued Products 145
Ischemia Reperfusion Injury - Product Development Milestones 146
Appendix 153

List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H2 2017
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corp, H2 2017
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2017
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H2 2017
Ischemia Reperfusion Injury - Pipeline by Hope Pharmaceuticals Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Kowa Company Ltd, H2 2017
Ischemia Reperfusion Injury - Pipeline by NovelMed Therapeutics Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Omeros Corp, H2 2017
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd, H2 2017
Ischemia Reperfusion Injury - Pipeline by Orexo AB, H2 2017
Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H2 2017
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2017
Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Ischemia Reperfusion Injury - Pipeline by Recordati SpA, H2 2017
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Ischemia Reperfusion Injury - Dormant Projects, H2 2017
Ischemia Reperfusion Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017
Ischemia Reperfusion Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017
Ischemia Reperfusion Injury - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Ischemia Reperfusion Injury, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *